RGLS
Companies
NASDAQ
Regulus Therapeutics Inc.
Health Care
$8.21
+$6.65 (+426.28%)
Price Chart
Overview
About RGLS
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Market Cap
$146.0M
Volume
8.9M
Avg. Volume
18.7M
P/E Ratio
-6.504132
Dividend Yield
0.00%
Employees
38.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.25
Moderate Correlation
Volatility
High (0.85)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RGLS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$146.0M
Volume8.9M
P/E Ratio-6.50
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025